EBV induces CD95 expression and the C95 gene is regulated by NF−κB, STAT1 and/or p53.
Introduction
Epstein Barr Virus (EBV) was first reported to be associated with Burkitt´s Lymphoma (BL).
EBV is able to immortalize B-cells both in vitro and in vivo. EBV is also the aetiological agent of infectious mononucleosis, a benign viral disease of young adults that regresses spontaneously. In most cases, primary EBV infection is asymptomatic. Epidemiological and serological studies showed that EBV is widely distributed in humans around the world and that more than 95% of adults have been infected by EBV in their past. The ability to grow EBV-infected B-cell lines from PBMCs of EBV-seroconverted healthy subjects leads to the conclusion that this virus persists as a clinically silent infection for the lifetime of the infected host 1 . Nevertheless, it is of note that the virus remains continuously active in the immunocompetent individuals even though at very low levels 2 .
The EBV genome consists of a 180 kb double stranded DNA that remains stable in the cell nucleus in an episomal form. In vitro immortalisation of B-cells by EBV is due to the expression of a restricted set of viral genes, the so-called latency III program, coding for latent membrane proteins (LMP1, LMP2a, LMP2b), Epstein Barr Nuclear Antigens (EBNA1, 2, 3A, 3B, 3C, LP) and small non coding RNAs (EBERs), and leads to the establishment of lymphoblastoid cell lines (LCLs) 3 . Among these genes, EBNA1 is responsible for episomal maintenance of the EBV genome 4 . EBNA2 alone is responsible for the expression of the entire set of genes of the latency III program 5 . EBNA2 reroutes the Notch pathway by targeting RBP-jkappa 6 . EBNA2 is also the main viral transactivator of the BNLF1 gene coding for LMP1. LMP1 mimicks a constitutively activated receptor of the TNF receptor family through agregation of TRAF/TRADD molecules 7, 8 
. In vivo, the latency III program is
For personal use only. on September 24, 2017. by guest www.bloodjournal.org From expressed in newly infected B-blasts during primary EBV infection 9 . Most of these newly EBV-infected B-blasts are killed by cytotoxic T-cells. However, some EBV-infected B-blasts are considered to follow the normal process of B-cell maturation until the B-cell memory stage 10 . The B-cell memory compartment constitutes the EBV reservoir in humans. EBV is almost silent in its reservoir 10-12 . The immune response against EBV is associated with a dramatic oligoclonal increase in EBV specific CD8 cytotoxic T-cells during the initial phase of primary EBV infection [13] [14] [15] . CD95 is a member of the family of death receptors that initiate apoptosis by recruiting Fasassociated death domain protein (FADD), procaspase-8, procaspase-10, and cellular FLICE- 
Materials and Methods

Plasmid constructs and cDNA
The pRT-1 inducible vector was derived from the previously described CKR516 vector 36 in which the Eµ-RSV promoter was replaced by a Eµ-chicken-beta-actin promoter (Eµ-CAG promoter). The EBNA1 gene was added to favor maintenance of the vector as an episome also in EBV negative cells. The EGFP marker was replaced by an inactive truncated version of the NGF-R lacking the cytoplasmic domain (NGFR-t). The bi-directional tetracyclineinducible promoter drives the expression of both, NGFR-t and the cDNA of interest.
Complete description of these vectors is done elsewhere 37 . The cDNAs that were cloned into the Sfi-I sites coded for IκBα S32,36A (constitutively active form of IκBα) 38 , STAT1α (natural active isoform of STAT1), STAT1β (natural inactive isoform of STAT1) 36 , LMP1CT (a dominant negative mutant of LMP1 39 ) and LMP1wt. We have also cloned the cDNA coding for p53wt from the BL2 cell line into a Topo vector (Invitrogen, Cergy-Pontoise, France) after PCR amplification of its full length mRNA (p53sense: 5'-GATTGGCCAGACTGCCTTC-3', p53antisense :5'-CAAGGGTTCAAAGACCCAAA-3',).
After verifying its entire sequence, this cDNA was cloned into the Sfi-I sites of the pRT-1 vector.
Cell culture, treatment, transfection and cell sorting
The lymphoblastoid cell line PRI, the EBV negative Burkitt lymphoma cell line BL2, and the Stable transfection of cells and hygromycin selection were performed as described 36,38 .
Induction was stable after 4 weeks of selection. Varying with transfection, 60%-90% of the cells became NGFR-t positive after 24H treatment with 1µg/ml doxycyline.
Where indicated, NGFR-t expressing cells were purified following the manufacturer protocol(Miltenyi Biotech Macs microbeads, Auburn, CA, USA): briefly, viable cells were isolated by Ficoll-Paque Plus density gradient centrifugation (Eurobio, Les Ulis, France).
Cells were divided in two batches, one treated with doxycyline for 36H at 1µg/ml, and one without doxycyline. Both batches were then submitted in parallel to cell purification. 
Mixed lymphoproliferative reaction
Mixed Lymphoproliferative Reaction (MLR) was performed after purification of T-cells from PBMCs of 3 healthy volunteer donors, using an anti CD3 mAb (UCHT1 clone) using the same procedure described for purification of NGFR-t positive cells. Purification was assessed by triple labellings for CD3, CD4, CD8, and for CD3, CD19, CD5. Levels of remaining monocytes and B-cell was always less than 2%. Thirty million purified T-cells were 
Western blotting
Western blotting was performed as described elsewhere 36 . Hs00531110-m1 and Hs00234713-m1). The Abl1 gene was used as a reference gene for the control of amplification (product reference: Hs00245443-m1). All amplification steps were performed in duplicate. The calculated relative gene expression level was equal to 2 -DDCT , where DDCT is the delta delta CT and CT the cycle threshold, as previously described 36,41 .
Electrophoretic mobility shift assay (EMSA)
Nuclear and cytoplasmic extracts were performed in parallel as described 42 . Gel shift experiments were performed with 20µg of nuclear proteins as described 42,43 with the PRE oligonucleotide containing the 2 κΒ sites of the HIV enhancer.
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Results
Relationship between CD95 and LMP1 expression in EBV-latency III immortalized B-cells
CD95 expression has been reported to be induced in EBV-infected B-cells 33 raising the question of its regulation in these cells. In EREB2-5 cells in which the latency III program is under the control of an estrogen-regulatable EBNA2 protein 6 , expression of CD95 was markedly induced by addition of estrogen ( figure 1A ). This induction was preceded by induction of LMP1, the major EBV transforming protein and a direct target gene product of EBNA2 ( figure 1A ). Importantly, CD95 expression was also induced at the mRNA level Since NF−κB is the main transcriptional system regulated by LMP1, we attempted to evaluate the NF−κB dependence of p53 and STAT1 activation. We found that inhibition of NF−κB by IκBα S32,36A was associated with a marked decrease in both STAT1 protein and tyrosine 701 STAT1 phosphorylation (figure 4A), as well as a decrease in serine 15 phosphorylation of p53 (figure 4B). These results suggest that activation of both STAT1 and p53 is dependent on NF−κB activation in these cells. We then assessed the effect of NF-κB inhibition on transfected cells (compare figure 4C with figure 3A ). CD95 mRNA levels were markedly increased after IFNγ treatment ( figure 4C ). This effect was significantly reduced in presence of Bay11 (figure 4A). Fludarabine* treatment induced a moderate increase of CD95 mRNA levels in parental PRI cells (compare figure 4C and 3C ), an effect that was also affected by Bay11 treatment (figure 4C). Altogether, these results indicate that NF-κB is likely to control CD95 expression both directly and indirectly via secondary STAT1 and p53 activation and that regulation of CD95 by either STAT1 or p53 inducers may depends on NF-κB.
CD95 targeting in latency III EBV-immortalized B-cells
In a next step, we wanted to assess the function of CD95 in LCL cells. We first wanted to link LMP1-induced CD95 expression with CD95-mediated apoptosis. We analyzed the induction of CD95-mediated apoptosis in LCL cells stably transfected with either pRT-1-LMP1CT or pRT-1-LMPwt. Treatment with the agonistic mAb BG27 against CD95 clearly induced apoptosis of LCL PRI cells, whereas the anti-CD95 neutralising mAb BD29 had virtually no effect ( figure 5) . Induction of LMP1CT, the dominant negative of LMP1, had a slight effect on the level of apoptosis in LCL PRI cells, an effect detectable mainly at 48H that more than likely reflected the inhibition of LMP1 signaling by LMP1CT. LMP1CT overexpression was associated with a decrease in CD95-mediated apoptosis, probably related to a decrease in the density of surface membrane CD95 molecules. LMP1wt induction was associated with an increase in spontaneous apoptosis of transfected cells (figure 5), reflecting the known toxicity of LMP1 46 . Over-expression of LMP1wt was associated with a marked increase in CD95-mediated apoptosis at 48H (figure 5), suggesting that LMP1-induced CD95 expression is associated with sensitization of cells to CD95-mediated apoptosis. These results show that the CD95 apoptosis pathway is functional in EBV latency III immortalized B cells. Moreover, this suggests that susceptibility of LCL cells to CD95 mediated apoptosis is related to the surface membrane density of CD95 molecules, a parameter that is under the control of LMP1.
We then analyzed the induction of CD95-mediated apoptosis in LCL cells stably transfected either with pRT-1-IκBα S32,36A or pRT-1-STAT1β. In the absence of doxycyline, treatment of cells with the agonistic monoclonal antibody BG27 against CD95 resulted in nearly 50% apoptosis induction ( figure 6 ). In pRT-1-IκBα S32,36A stably transfected cells, inhibition of NF−κB by doxycyline pre-treatment markedly sensitized cells to CD95-mediated apoptosis (figure 6). As previously shown ( figure 3A) , inhibition of NF-κB marginally or moderately 
Discussion
In this report, we present a comprehensive study of the regulation of CD95 in EBV-latency III immortalized B-cells. Our results show that LMP1 is able to control CD95 expression through the activity of NF−κB, STAT1 and p53 and that STAT1 and p53 are under the control of NF−κB. Furthermore, we show that CD95 expression allows T-cells to kill EBV-immotalized B-cells.
To perform this study, we used a conditional expression system in a systematic manner in order to control the activity of a given factor that has been putatively involved in the control of CD95 expression. To control the whole EBV latency III program, we have used the EREB2-5 cell line harbouring an estrogen regulatable EBNA2 protein 6 . To control the activity of LMP1, NF−κB, STAT1 and p53, we constructed a novel inducible episomal vector, called pRT-1, that carries all the elements for conditional gene expression including the gene of interest on one EBV-derived episomally replicating plasmid 37 , including the rtTA2s-M2 cassette 48-50 and a bidirectional doxycycline regulatable promoter that allowed simultaneous expression of the gene of interest and a second gene, e.g. the truncated NGF receptor gene (NGFR-t) used as surrogate marker. Using these versatile vectors, we were able to control LMP1, NF−κΒ, p53 and STAT1 activity in both EREB2-5 cells and the LCL PRI, providing useful tools for the understanding of CD95 regulation in EBV-infected B-cells.
Interestingly, we found that, contribution of LMP1 to the regulation of CD95 expression was higher than that of each of the 3 transcriptional factors individually, which may likely correspond to a synergistic or cooperative interaction between these factors in the regulation of the CD95 promoter. Not only T-cell defects, but also defects in induction and execution of apoptosis may lead to emergence of EBV-associated lymphoproliferative disease. This is illustrated by the frequency of EBV-associated lymphomas in Ataxia Telangiectasia syndrome which corresponds to secondary mutations of ATM resulting in a defect of p53 activation in the case of DNA strand breaks 55-57 . Atypical lymphoproliferative syndrome (ALPS), a recently described entity, is a genetic disorder that involves the Fas-Fas ligand pathway of cell death, that was first reported to be related to CD95 germline mutations 58,59 . ALPS may be associated with chronic active EBV infection in children, a disease caused by a defect of CTL and NK killing 23 . The risk of developing non Hodgkin and Hodgkin lymphomas in ALPS is 14 and 51 times higher, respectively, than in normal subjects 60 . A significant proportion of these tumors are associated with EBV, and it has been speculated that a defect in the CD95 mediated pathway for killing of virally infected cells might allow EBV to persist 60 . Therefore, EBV-latency III immortalized B-cells harbor both pro and anti-apoptotic activated factors, with reciprocal inhibition and/or activation between them, resulting in a dynamic equilibrium that is likely to be evolutive according to the microenvironment, being able to lead the infected cell to apoptosis or proliferation.
Altogether, our results indicate that LMP1 is responsible for CD95 up-regulation through the activation of NF−κB activation. Moreover, our results suggest that NF−κΒ also controls STAT1 activation and contributes to p53 activation, and that both STAT1 and p53 activation positively regulate CD95 expression in LCL cells. Both, p53 and STAT1 favor apoptosis, whereas NF−κB is anti-apoptotic. The CD95 mediated apoptosis pathway is functional and is likely to participate in T-cell killing of EBV-latency III immortalized B-cells. These results, with some from the literature, show that EBV both protects infected cells against apoptosis through NF−κB activation and renders them susceptible to future CD95 mediated apoptosis. Results were confirmed by quantification of sub-G1 peak of cells (not shown). 
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